Serum Levels of Matrix Metalloproteinase (MMP) 9, a Risk Factor for Acute Coronary Syndrome, Are Reduced Independently of Serum MMP-3 by Anti-TNF-α Antibody (Infliximab) Therapy in Patients With Rheumatoid Arthritis

• Main Authors: Takuya Kotani (Author), Tohru Takeuchi (Author), Shinji Takai (Author), Shuzo Yoshida (Author), Kenichiro Hata (Author), Koji Nagai (Author), Daisuke Wakura (Author), Kentaro Isoda (Author), Shigeki Makino (Author), Toshiaki Hanafusa (Author)
• Format: Book
• Published: Elsevier, 2012-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Matrix metalloproteinase 9 (MMP-9) is a risk factor for cardiovascular events. The serum MMP-9 levels were measured before and 2 weeks after treatment with infliximab (3 mg/kg) in 12 rheumatoid arthritis (RA) patients. The serum average MMP-9 level was 238.5 ng/ml before treatment with infliximab in...